These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 21764798)

  • 1. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate.
    Ezziddin S; Sabet A; Heinemann F; Yong-Hing CJ; Ahmadzadehfar H; Guhlke S; Höller T; Willinek W; Boy C; Biersack HJ
    J Nucl Med; 2011 Aug; 52(8):1197-203. PubMed ID: 21764798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis.
    Sabet A; Khalaf F; Haslerud T; Al-Zreiqat A; Sabet A; Simon B; Pöppel TD; Biersack HJ; Ezziddin S
    Am J Nucl Med Mol Imaging; 2013; 3(5):437-45. PubMed ID: 24116352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Sabet A; Ezziddin K; Pape UF; Ahmadzadehfar H; Mayer K; Pöppel T; Guhlke S; Biersack HJ; Ezziddin S
    J Nucl Med; 2013 Nov; 54(11):1857-61. PubMed ID: 24009272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.
    Sabet A; Dautzenberg K; Haslerud T; Aouf A; Sabet A; Simon B; Mayer K; Biersack HJ; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1238-46. PubMed ID: 25808630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement.
    Sabet A; Khalaf F; Yong-Hing CJ; Sabet A; Haslerud T; Ahmadzadehfar H; Guhlke S; Grünwald F; Biersack HJ; Ezziddin S
    Nuklearmedizin; 2014; 53(2):54-9. PubMed ID: 24777355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy.
    Ezziddin S; Meyer C; Kahancova S; Haslerud T; Willinek W; Wilhelm K; Biersack HJ; Ahmadzadehfar H
    J Nucl Med; 2012 Nov; 53(11):1663-9. PubMed ID: 22988059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours.
    Ezziddin S; Khalaf F; Vanezi M; Haslerud T; Mayer K; Al Zreiqat A; Willinek W; Biersack HJ; Sabet A
    Eur J Nucl Med Mol Imaging; 2014 May; 41(5):925-33. PubMed ID: 24504504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival predictors of
    Swiha MM; Sutherland DEK; Sistani G; Khatami A; Abazid RM; Mujoomdar A; Wiseman DP; Romsa JG; Reid RH; Laidley DT
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):225-236. PubMed ID: 34110489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage peptide receptor radionuclide therapy with [
    van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
    Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
    Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with
    Bergsma H; van Lom K; Raaijmakers MHGP; Konijnenberg M; Kam BLBLR; Teunissen JJM; de Herder WW; Krenning EP; Kwekkeboom DJ
    J Nucl Med; 2018 Mar; 59(3):452-458. PubMed ID: 28775205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.
    Pach D; Sowa-Staszczak A; Kunikowska J; Królicki L; Trofimiuk M; Stefańska A; Tomaszuk M; Głowa B; Mikołajczak R; Pawlak D; Jabrocka-Hybel A; Hubalewska-Dydejczyk AB
    Radiother Oncol; 2012 Jan; 102(1):45-50. PubMed ID: 21885142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
    Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
    J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate.
    Teunissen JJ; Kwekkeboom DJ; Krenning EP
    J Clin Oncol; 2004 Jul; 22(13):2724-9. PubMed ID: 15226340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
    Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW
    Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
    Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
    Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Radiological Response to Peptide Receptor Radionuclide Therapy on Overall Survival in Patients With Metastatic Midgut Neuroendocrine Tumors.
    Yalchin M; Oliveira A; Theocharidou E; Pencharz D; Navalkissoor S; Quigley AM; Walker M; Caplin M; Toumpanakis C
    Clin Nucl Med; 2017 Mar; 42(3):e135-e141. PubMed ID: 27922860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
    Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
    J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.